4
ALL4
Osteal TherapeuticsYear
4
ALL1
20243
2023DEALS // DEV.
4
ALL2
Deals2
DevelopmentsCountry
4
ALL4
U.S.A4
ALL1
Asteroid Partners1
Johnson & Johnson2
Not ApplicableTherapeutic Area
4
ALL3
Infections and Infectious Diseases1
MusculoskeletalStudy Phase
4
ALL4
Phase IIDeal Type
2
ALL1
Series C Financing1
Series D FinancingProduct Type
4
ALL4
Small moleculeDosage Form
0
ALLLead Product
4
ALL4
Vancomycin HydrochlorideTarget
0
ALLLead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Series D Financing
Osteal Therapeutics Raises $50M To Support Lead Candidate Launch
Details : The financing will advance the development of Osteal’s portfolio of therapies, including the submission of NDA and accelerated commercial launch of VT-X7 for treating PJI of the hip and knee.
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Series D Financing
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJ...
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Asteroid Partners
Deal Size : $23.0 million
Deal Type : Series C Financing
Osteal Therapeutics Closes $23M Series C Financing
Details : The proceeds will support NDA submission and preparation for commercial launch of company's VT-X7, a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin hydrochloride and tobramycin, for periprosthetic joint...
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Asteroid Partners
Deal Size : $23.0 million
Deal Type : Series C Financing
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJ...
Brand Name : VT-X7
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 07, 2023
Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?